Back to News
Market Impact: 0.35
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In
Source: benzinga.com
Healthcare & BiotechRegulation & LegislationCorporate Guidance & Outlook
The FDA extended by three months its review of Exelixis's NDA for zanzalintinib combined with atezolizumab in metastatic colorectal cancer. The delay postpones a potential approval decision and near-term commercialization catalyst for Exelixis, creating additional regulatory uncertainty for the drug program.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment
EXEL-0.45
More News
- Exelixis stock falls as FDA extends zanzalintinib review
- Apollo in talks to buy J&J orthopedics unit for nearly $20 billion
- Surging cloud revenue boosted Oracle’s quarterly results. Here’s what analysts are saying
- Oracle jumps 6% after reporting 30% revenue growth fueled by AI cloud demand
- Apollo Global in talks to acquire J&J’s orthopedics unit, Bloomberg News reports
- US legislators push AI safety laws amid human extinction warnings